Business
NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity
EDEN PRAIRIE, Minn., June 2, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC; NeuroOne or the Company), a medical technology
About this update from Neuroone Medical Technologies Corporation
[{"type":"text","content":"EDEN PRAIRIE, Minn., June 2, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the formation of a six member advisory board of leading neurosurgeons to assist in the completion of development of a radio frequency ablation electrode intended to record and ablate brain tissue linked to causing seizure activity.\n\n \n \n \n \n \n \n\n \nThe six members that have been appointed to the advisory board are as follows:\nDr. Daniel Couture, Wake Forest Baptist Health Dr. Gerald Grant, Stanford University Medical Center Dr. Bob Gross, Emory University Dr. Zachary Levine, Holy Cross Health, George Washington University Dr. Guy McKhann, New York Presbyterian Hospital, Columbia University Dr. Jamie Van Gompel, Mayo ClinicNeuroOne CEO Dave Rosa says, \"We are honored to have an opportunity to partner with such distinguished neurosurgeons who I believe will be extremely helpful in accelerating our ablation electrode technology program. Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure. The electrode is also expected to save time, cost and potentially improve outcomes, adding value to both patients and physicians that could benefit from this technology.\"\nAbout NeuroOne NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .\nOn February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020 . In addition to acquiring exclusive global distribution rights to NeuroOne's Evo™ (Evo) patented electrode technology, the partnership also offered the potentia...